CoChat

A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs

Moghaddam, Mehran, Tang, Yang, O’Brien, Zhihong, Richardson, Samantha, Bacolod, Maria, Chaturedi, Prasoon, Apuy, Julius, Kulkarni, Ashutosh · 2014 · Drug Metabolism Letters
Cited by 18

The DOI matches its Crossref record.

Abstract

The in vitro and in vivo preclinical ADME properties of 10 clinically late stage or marketed covalent inhibitors were evaluated in order to define advancement criteria for discovery of future drugs in this arena. Our studies revealed the following: After incubating with S9 fractions for 30 minutes, the rat and human in vitro stability for these compounds ranged from 1% to 100%. The blood stability ranged from 30% to 100%. There was a broad range of CYP inhibition with prevalence for time-dependent inhibition of at least one enzyme. The Caco-2 permeability (A→B) ranged from negligible (0.6 x 10-6 cm/s) to highly permeable (31 x 10-6 cm/s) and the efflux ratio also varied widely (0.2-30). Most of the compounds were highly protein bound in both rat and human with binding ≥ 90%. Rat plasma clearance for the 10 compounds ranged from slow (11 mL/min/kg) to very rapid (350 mL/min/kg). The Vss ranged from low (0.67 L/kg) to very high (115 L/kg). MRT’s also ranged from short (0.5 hr) to long (7.4 hr). The oral exposures also showed a very broad range with Cmax’s ranging from 0.01-77 μM and exposure levels ranging from 0.03-106 μM.hr. In conclusion, the wide range in in vitro and in vivo ADME data makes these particular ADME assays non-discriminatory in the selection of promising compounds. In our opinion, non-traditional assays such as target mass modification, target confirmation by amino acid sequencing, cellular target occupancy, and target turnover rate data in combination with the pharmacokinetic profiles are the critical considerations for progression of irreversible compounds in early discovery. Biography: Mehran Moghaddam, PhD, is the head of Discovery DMPK at Celgene, a global biopharmaceutical company with products in oncology and immune-inflammatory related diseases. He has 18 years of industrial experience with DuPont, Pfizer, and Celgene. His expertise includes animal experimentation, pharmacokinetics, metabolism, metabolite/catabolite identification, and bioanalysis of small and macro-molecules. Keywords: ADME, covalent, discovery, irreversible, mass-modification, pharmacokinetics, screening.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1872312808666140317151735

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 18

Metadata

Authors
Moghaddam, M., Tang, Y., O’Brien, Z., Richardson, S., Bacolod, M., Chaturedi, P., Apuy, J., & Kulkarni, A.
Venue
Drug Metabolism Letters
Published
2014-03-17
Volume
8
Issue
1
Pages
19-30
ISSN
1872-3128 (ISSN-L)
OpenAlex
W2145454199
Cited by
18
References
0
FWCI
4.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs. https://app.cochat.ai/papers/10.2174/1872312808666140317151735
The paper
Moghaddam, M., Tang, Y., O’Brien, Z., Richardson, S., Bacolod, M., Chaturedi, P., Apuy, J., & Kulkarni, A. (2014). A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs. Drug Metabolism Letters. https://doi.org/10.2174/1872312808666140317151735

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.